OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM

About this update from Ose Immunotherapeutics Sa

[{"type":"image","alt":"OSE Immunotherapeutics","displaySize":"","headline":null,"caption":"OSE Immunotherapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/h55Oot7mWh39J7Yvj1GueA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb","width":300,"height":100}},"lazy":false},{"type":"text","content":"OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM","length":127,"tagName":"p"},{"type":"text","content":"","length":0,"tagName":"p"},{"type":"text","content":"Nantes, August 29, 2025, 8:00 a.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today published a comprehensive Questions and Answers document in advance of its Annual General Meeting (AGM) convened on September 30, 2025. The document provides clear, factual information about financing, governance, scientific development and the Company’s strategy.","length":370,"tagName":"p"},{"type":"text","content":"OSE Immunotherapeutics’ strategy is to capitalize on its two flagship programs, Tedopi® and Lusvertikimab, expected to advance through a combination of strategic partnerships and appropriate financing mechanisms, while continuing to progress its productive Research activities. The Company’s late-stage programs are designed to create significant value and position OSE as a leading European biotech in the field of immunotherapy in oncology and inflammation.","length":459,"tagName":"p"},{"type":"text","content":"However, OSE Immunotherapeutics has been the target of intense shareholder activism, characterized by an unprecedented public misinformation campaign led by a group of minority shareholders. These tactics have generated confusion and distorted facts in the lead-up to the Annual General Meeting (AGM).","length":301,"tagName":"p"},{"type":"text","content":"Didier Hoch, Chairman of OSE Immunotherapeutics, commented: “The AGM on September 30 is a decisive moment for OSE. Shareholders are being asked to choose between a credible, value-creating strategy, grounded in advancing Tedopi® and Lusvertikimab and securing the right partnerships when pivotal dat...

More updates from Ose Immunotherapeutics Sa